

2020

Retinal Imaging in Alzheimer's and Neurodegenerative Diseases

Peter J. Snyder

University of Rhode Island, pjsnyder@uri.edu

Jessica Alber

University of Rhode Island, jalber@uri.edu

Clemens Alt

Lisa J. Bain

Brett E. Bouma

See next page for additional authors

Follow this and additional works at: https://digitalcommons.uri.edu/bps_facpubs

Creative Commons License



This work is licensed under a [Creative Commons Attribution-Noncommercial 4.0 License](https://creativecommons.org/licenses/by-nc/4.0/)

Citation/Publisher Attribution

Snyder, PJ, Alber, J, Alt, C, et al. Retinal imaging in Alzheimer's and neurodegenerative diseases. *Alzheimer's Dement.* 2020; 1– 9. <https://doi.org/10.1002/alz.12179>

This Article is brought to you for free and open access by the Biomedical and Pharmaceutical Sciences at DigitalCommons@URI. It has been accepted for inclusion in Biomedical and Pharmaceutical Sciences Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.

Authors

Peter J. Snyder, Jessica Alber, Clemens Alt, Lisa J. Bain, Brett E. Bouma, Femke H. Bouwman, Delia Cabrera DeBuc, Melanie C.W. Campbell, Maria C. Carrillo, Emily Y. Chew, M. Francesca Cordeiro, Michael R. Dueñas, Brian M. Fernández, Maya Koronyo-Hamaoui, Chiara La Morgia, Roxana O'Carare, Srinivas R. Sadda, Peter van Wijngaarden, and Heather M. Snyder

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](#) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2020 The Authors. *Alzheimer's & Dementia* published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association

Alzheimer's Dement. 2020;1-9.

wileyonlinelibrary.com/journal/alz | 1

to read: "Chief Public Health Officer, American Optometric Association, Washington, D.C."

biological changes associated with AD, and for tracking progression of disease severity over time. As different retinal imaging modalities provide different types of structural and/or functional information, the discussion reflected on these modalities and their respective strengths and weaknesses. Discussion further focused on the importance of defining the context of use to help guide the development of retinal biomarkers. Moving from research to context of use, and ultimately to clinical evaluation, this article outlines ongoing retinal imaging research today in Alzheimer's and other brain diseases, including a discussion of future directions for this area of study.

KEYWORDS

Alzheimer's disease, biomarkers, early detection, eye, neurodegeneration, retina, retinal imaging